Coming in 2027
- Pseudomonas aeruginosa phages
- We have phages capable of killing all isolates of P. aeruginosa we have found in the USA, including a large collection of MDR and XDR isolates from the CDC.
- We are developing a phage cocktail of phages capable of treating 85-90% of P. aeruginosa, isolates in the USA.
- Contact us at phages@ucsd.edu for further information.
Coming in 2027/2028
- Klebsiella spp. phages
- We developed evolved phages with significant activity against Klebsiella pneumoniae.
- There are still many gaps in our Klebsiella phage collection.
- We are continuing to fill in the gaps in this phage collection.
- Contact us at phages@ucsd.edu for further information.
A Couple of Months Away
- Achromobacter xylosoxidans phages
- Soon to be purified and ready to be used
- We estimate that the cocktail we are designing can treat approximately 90-95% of the Achromobacter isolates across the country.
- Contact us at phages@ucsd.edu for further information.
Coming in 2027
- Salmonella spp. phages
- We have phages capable of killing all isolates of Salmonella spp. we have found across the globe.
- We are developing a phage cocktail capable of treating all Salmonella isolates.
- Contact us at phages@ucsd.edu for further information.
Coming in 2027
- Escherichia coli phages
- We are developing an E. coli phage collection mostly targeting uropathogenic E. coli.
- The primary goal is to manage those with recurrent urinary tract infections, but likely will have uses for hardware and device infections as well.
- Thus far, we can already kill most uropathogenic E. coli isolates and are currently developing a cocktail.
- Contact us at phages@ucsd.edu for further information.
Available now
- Staphylococcus aureus phages
- These are already purified and ready to be used.
- We estimate that we have phages capable of treating 94-98% of S. aureus, including MRSA, isolates across the world.
- Contact us at phages@ucsd.edu for further information.